

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 January 2022 (27.01.2022)



(10) International Publication Number
WO 2022/019828 A1

(51) International Patent Classification:

A61K 31/352 (2006.01) C12Q 1/37 (2006.01)
A61P 31/14 (2006.01)

(21) International Application Number:

PCT/SG2021/050295

(22) International Filing Date:

27 May 2021 (27.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202007071Q 23 July 2020 (23.07.2020) SG

(71) Applicant: NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(72) Inventor: ST. JOHN, Ashley, Lauren; c/o Duke-NUS Medical School, 8 College Road, Singapore 169857 (SG).

(74) Agent: DOWSING, Bruce, John; Marks & Clerk Singapore LLP, Tanjong Pagar Post Office, P.O. Box 636, Singapore 910816 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES

FIGURE 11



(57) Abstract: The present invention relates to treatment of coronavirus-induced disease, specifically COVID-19 disease, wherein the disease is characterized by mast cell degranulation, acute inflammation, pulmonary and/or vascular pathologies. The treatment comprises administering to a subject a composition comprising a mast cell stabilizer and/or inhibitor of mast cell products, such as TY-51469, nafamostat mesylate, cromolyn, or ketotifen. The invention also provides a method of diagnosing a subject as having SARS-CoV-2, the method comprising determining the level and/or activity of a mast cell protease such as chymase or tryptase in the serum from a subject.

WO 2022/019828 A1